Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.35 USD | +0.79% | +5.39% | -26.03% |
04-15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
02-26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.03% | 1.56B | |
-16.10% | 11.41B | |
-30.20% | 2.3B | |
-14.31% | 2.16B | |
+36.95% | 1.19B | |
-2.40% | 760M | |
-19.00% | 506M | |
-38.57% | 444M | |
+13.72% | 339M | |
+15.53% | 227M |
- Stock Market
- Equities
- VCYT Stock
- News Veracyte, Inc.
- Sector Update: Health Care Stocks Rising Just Ahead of Monday Close